A haemagglutination test for rapid detection of antibodies to SARS-CoV-2

Townsend, Alain; Rijal, Pramila; Xiao, Julie; Tan, Tiong Kit; K-Ya., Huang; Schimanski, Lisa; Huo, Jiandong; Gupta, Nimesh; Rahikainen, Rolle; Matthews, Philippa C.; Crook, Derrick W.; Hoosdally, Sarah; Dunachie, Susanna; Barnes, Eleanor; Street, Teresa; Conlon, Christopher P.; Frater, John; Arancibia‐Cárcamo, Carolina V.; Rudkin, Justine; Stoesser, Nicole; Karpe, Fredrik; Neville, Matt J.; Ploeg, Rutger J.; Oliveira, Marta; Roberts, David; Lamikanra, Abigail; Tsang, Hoi Pat; Bown, Abbie; Vipond, Richard; Mentzer, Alexander J.; Knight, Julian C.; Kwok, Andrew; Screaton, Gavin; Mongkolsapaya, Juthathip; Dejnirattisai, Wanwisa; Supasa, Piyada; Klenerman, Paul; Dold, Christina; Baillie, J Kenneth; Moore, Shona C.; Pjm., Openshaw; Semple, Malcolm G; Lcw., Turtle; Ainsworth, Mark; Allcock, Alice; Beer, Sally; Bibi, Sagida; Skelly, Donal; Stafford, Lizzie; Jeffrey, Katie; O’Donnell, Denise; Clutterbuck, Elizabeth A.; Espinosa, Alexis; Mendoza, Maria Fernandez; Georgiou, Dominique; Lockett, Teresa; Martínez, José Luis; Perez, Elena; Sánchez, Verónica; Scozzafava, Giuseppe; Sobrinodiaz, Alberto; Thraves, Hannah; Joly, Etienne

doi:10.1038/s41467-021-22045-y

Cited by 59 publications

(98 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…EUROimmun IgG spike enzyme‐linked immunosorbent assay (ELISA; Lübeck, Germany), Vitros IgG spike assay (Ortho Clinical Diagnostics, Raritan, New Jersey), Elecsys anti‐SARS‐CoV‐2 S assay (Roche, Basel, Switzerland), and GenScript surrogate virus neutralization test (Piscataway, New Jersey) were performed as specified by the manufacturer. A hemagglutination test (HAT) was based on red cell agglutination to detect antibodies to receptor binding domain (RBD) of the SARS‐CoV‐2 14 …”

Section: Methodsmentioning

confidence: 99%

Comparability of six different immunoassays measuring SARS‐CoV‐2 antibodies with neutralizing antibody levels in convalescent plasma: From utility to prediction

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background: Convalescent plasma (CP) therapy for coronavirus disease (COVID-19) provides virus-neutralizing antibodies that may ameliorate the outcome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. The effectiveness of CP likely depends on its antiviral neutralizing potency and is determined using in vitro neutralizing antibody assays.Study design and methods: We evaluated abilities of three immunoassays for anti-spike antibodies (EUROimmun, Ortho, Roche), a pseudotype-based neutralization assay, and two assays that quantify ACE2 binding of spike Abbreviation: SARS-CoV-2, COVID-19, neutralising antibody testing; convalescent plasma. Abigail Lamikanra and Dung Nguyen shared first authors.

show abstract

Section: Methodsmentioning

confidence: 99%

Comparability of six different immunoassays measuring SARS‐CoV‐2 antibodies with neutralizing antibody levels in convalescent plasma: From utility to prediction

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…The haemagglutination test (HAT) 13 was used to investigate the SARS-CoV-2 speci c antibodies to the RBD of the ancestral virus (Wuhan-like, pre alpha) and to the VOC alpha (B. controls (monoclonal antibodies CR3022 and EY-6A) were included in each run. Plates were incubated to allow red blood cells to settle for 1 hr and were read by tilting the plate for 30s and photographing.…”

Section: Haemagglutination Test (Hat)mentioning

confidence: 99%

“…Here, we correlate the low-cost rapid hemagglutination test (HAT) 13 with neutralisation of the ancestral Wuhan-like strain in two large independent cohorts of infected patients. In the HAT assay, the RBD domain is linked to a monomeric antierythrocyte single domain nanobody.…”

Section: Introductionmentioning

confidence: 99%

A Rapid Antibody Screening Haemagglutination Test for Predicting Immunity to Sars CoV-2 Variants of Concern

Ertesvåg¹,

Xiao²,

Zhou³

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Evaluation of susceptibility to emerging SARS-CoV-2 variants of concern (VOC) requires rapid screening tests for neutralising antibodies which provide protection. We developed a receptor-binding domain specific hemagglutination test (HAT) which correlated with neutralising antibodies (R=0.74-0.82) in two independent cohorts from 798 convalescents. Home-dwelling older individuals (80-99 years, n=89) had significantly lower antibodies after one dose of BNT162b2 vaccine than younger adult vaccinees (n=310) and naturally infected individuals (n=307). The second vaccine dose boosted and broadened the antibody repertoire to VOC in naïve but not previously infected, older and younger adults. >75% of older adults responded after two vaccinations to alpha and delta, but only 59-62% to beta and gamma, compared to 96-97% of younger vaccinees and 68-76% of infected individuals. Overall, the HAT provides a surrogate marker for neutralising antibodies, could be used as a simple inexpensive, rapid test, rapidly adaptable to emerging VOC for large-scale evaluation of potentially diminishing vaccine effectiveness.

show abstract

“…Further, as more specific treatments are identified, JS7 and variants could prove useful antigens in rapid diagnostic tests to distinguish severely ill patients with COVID-19 from those suffering from other ailments that could have similar symptoms. We also suggest that JS7 or variants thereof could be incorporated into assays previously developed using recombinant RBD, such as haemagglutinin assays [ 59 , 60 ].…”

Section: Discussionmentioning

confidence: 99%

Synthetic proteins for COVID-19 diagnostics

et al. 2021

View full text Add to dashboard Cite

There is an urgent need for inexpensive, rapid and specific antigen-based assays to test for vaccine efficacy and detect infection with SARS-CoV-2 and its variants. We have identified a small, synthetic protein (JS7), representing a region of maximum variability within the receptor binding domain (RBD), which binds antibodies in sera from nine patients with PCR-verified COVID-19 of varying severity. Antibodies binding to either JS7 or the SARS-CoV-2 recombinant RBD, as well as those that disrupt binding between a fragment of the ACE2 receptor and the RBD, are proportional to disease severity and clinical outcome. Binding to JS7 was inhibited by linear peptides from the RBD interface with ACE2. Variants of JS7, such as E484 K or N501Y, can be quickly synthesized in a pure form in large quantities by automated methods. JS7 and related synthetic antigens can provide a basis for specific diagnostics for SARS-CoV-2 infections.

show abstract

A haemagglutination test for rapid detection of antibodies to SARS-CoV-2

Cited by 59 publications

References 43 publications

Comparability of six different immunoassays measuring SARS‐CoV‐2 antibodies with neutralizing antibody levels in convalescent plasma: From utility to prediction

Comparability of six different immunoassays measuring SARS‐CoV‐2 antibodies with neutralizing antibody levels in convalescent plasma: From utility to prediction

A Rapid Antibody Screening Haemagglutination Test for Predicting Immunity to Sars CoV-2 Variants of Concern

Synthetic proteins for COVID-19 diagnostics

Contact Info

Product

Resources

About